Get the Weekly Intelligence Brief — top committee picks every Sunday.
STE · NYSE · STOCK

Steris (STE) Stock Analysis

Healthcare Updated September 05, 2026
$224.63
52W $195.14 – $269.44
49/100
$22.11B
27.7
0.91
AI Committee Verdict
Watch
49/100
Conviction: Contested · 50% agreement · 4 analysts
+0.4%
-7.2%
0.06:1
Contested

Is STE Bullish or Bearish?

Mixed. Innellis AI committee rates Steris (STE) Watch with a composite score of 49/100 , based on 4 analysts with 50% agreement. Last updated September 05, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +11.04 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -8.96 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Growth Analyst remains cautious — growth rate is decelerating quarter over quarter -- the trend line matters more than the level. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
Insufficient data for bull case.
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • RSI at 30 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Price trading below the lower Bollinger Band -- stretched to the downside — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 05, 2026
Overall Committee Score
49/100
Agreement
50%
Analysts
4
Conviction
Contested
Sector Rank
Top 96%
of 192 Healthcare peers
Growth Analyst bearish
35 / 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bearish
38 / 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 30 is in oversold territory (could mean either capitulation or a bounce setup)
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3059.07)
Open Full Terminal →

Investment Thesis Evolution

Committee score weakened from 58.2 to 49.0.

Analyst-level changes:
  • Growth Analyst: stance neutral->bearish; score 53->35 (-18).
  • Risk Analyst abstained (was bullish at 80).
  • Value Analyst abstained (was neutral at 55).

Comparing 2026-09-04 to 2026-09-05 (1 day apart).

Technical Analysis

RSI (14)
29.6
Oversold
MACD Histogram
-1.659
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$210.23
Resistance
$227.64
Bollinger %B
-0.07
Below Lower Band
Price vs Moving Averages
EMA 9
$231.62 Below
EMA 21
$231.76 Below
EMA 50
$227.14 Below
EMA 200
$228.27 Below

Fundamental Analysis

Valuation
73
Growth
48
Profitability
64
Financial Health
96
Cash Flow
70
Valuation
P/E Ratio 27.7×
P/B Ratio 3.07×
PEG Ratio 1.11
Dividend Yield 1.14%
52W High $269.44
52W Low $195.14
Quality & Growth
ROE 1092.9%
ROA 731.2%
Gross Margin 4443.4%
Operating Margin 1890.8%
Revenue Growth YoY
Debt / Equity 0.28
AI Fundamental Assessment
P/E ratio of 27.7 (moderate relative to a 15-40x range); Price-to-book of 3.1x; PEG ratio of 1.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.9%; Return on assets of 7.3%; Net margin of 13.3%; Gross margin of 44.4%; Current ratio of 1.91 (healthy short-term liquidity); Debt-to-equity of 0.28; Free cash flow per share is positive (9.48); Most recent quarter beat estimates by 2.5%; EPS growth decelerating (+11.9% -> -8.5% QoQ); Average YoY EPS growth of 10.7%; Analyst estimates flat over recent quarters
Get the Full STE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime